At around six weeks after launch of Eli Lilly's (NYSE: LLY) interleukin (IL)-17 inhibitor Taltz (ixekizumab), one-third of surveyed dermatologists (n=99) report trialling the latest biologic, according to RealTime Dynamix: Psoriasis, an independent report issued by Spherix Global Insights on a quarterly basis that provides highly granular brand insights on the psoriasis market.
Although familiarity with Taltz and the ever-present reimbursement and access environment are reported as the leading barriers to adoption, more than 95% of the survey respondents anticipate using Taltz in their practice. Current users expect their use of Taltz to more than triple in the next three months, while during the same time frame more than 20% of non-users expect to initiate trial. [Taltz was launched in the USA in April, but Lilly did not report any sales figures on the drug with its second-quarter results that were released this week: Ed].
Switching from Stelara and Cosentyx
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze